CAPR Evp, General Counsel Karen Krasney Sells 24,100 Shares

Karen Krasney, the Executive Vice President and General Counsel at Capricor Therapeutics, Inc. (NasdaqGS: CAPR), sold 24,100 shares of the company on June 25, 2026. The transaction was not part of a pre-planned trading program. Shares of Capricor traded near $26.44 on Tuesday.

Capricor Therapeutics, Inc. Stock Up 191.8%

Shares of Capricor Therapeutics, Inc. traded near $26.44 on Tuesday. The biotechnology company, which focuses on developing therapies for Duchenne muscular dystrophy and other serious conditions, has a market cap of approximately $1.53 billion. Although the company isn't currently profitable, it has a forward P/E ratio of -41.17. The stock has experienced significant volatility, with a 52-week low of $4.30 and a high of $40.37. Its 50-day moving average is $30.15, while the 200-day moving average stands at $21.95.

Insider Buying and Selling at Capricor Therapeutics, Inc.

On June 25, 2026, both Karen Krasney, EVP and General Counsel, and Anthony Bergmann, CFO, were involved in transactions at Capricor Therapeutics. Krasney sold 24,100 shares at an average price of $30.38, while Bergmann also sold the same number of shares at the same price. Both insiders had previously acquired 24,100 shares at $3.18 each on the same day.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on Capricor Therapeutics, Inc. On March 13, 2026, B. Riley Securities maintained a 'buy' rating with a price target of $63.00. Piper Sandler reiterated its 'buy' rating with a target of $58.00 on the same day. Earlier in March, HC Wainwright & Co. also reiterated a 'buy' rating, setting a target price of $60.00. The consensus recommendation remains a 'strong buy', with a mean target price of $53.60 based on 10 analyst opinions.

About Capricor Therapeutics

Capricor Therapeutics, Inc. is a clinical-stage biotechnology firm based in San Diego, California. It focuses on developing innovative cell and exosome-based therapies for serious diseases like Duchenne muscular dystrophy. Its lead product candidate, Deramiocel, is in phase 3 clinical trials. The company also explores exosome-based treatments and vaccines, including a preclinical SARS-CoV-2 vaccine candidate. Dr. Linda Marbán leads the company as CEO, overseeing a team of 231 employees.

Bottom Line

Karen Krasney's recent share sale at Capricor Therapeutics highlights insider activity at the company. Despite the insider transactions, analysts remain bullish on the stock, maintaining 'buy' ratings with high price targets. Investors often track such transactions for insights, but remember that 13F and insider filings reflect past actions, not necessarily current positions.